✦ LIBER ✦

Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine

✍ Scribed by J. R. Veenendaal; A. D. Parkinson; N. Kere; K. H. Rieckmann; M. D. Edstein

Publisher: Springer
Year: 1991
Tongue: English
Weight: 430 KB
Volume: 41
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00265910

No coin nor oath required. For personal study only.

✦ Synopsis

Halofantrine is a new blood schizontocidal drug used for the treatment of multidrug-resistant falciparum malaria. The pharmacokinetics of halofantrine (HAL) and its principal metabolite, N-desbutylhalofantrine (BHAL), was investigated in 6 adult male patients of Melanesian origin with uncomplicated falciparum malaria. The patients received 500 mg of halofantrine hydrochloride at times 0, 6 and 12 h (total 1.5 g). All patients responded to treatment with a mean parasite clearance time of 52.7 h and a mean fever clearance time of 33.8 h. The following kinetic parameters (mean values) were determined for HAL and BHAL, respectively: maximum plasma concentration (Cmax) = 896 and 491 ng.ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h. Based on the clinical response the plasma concentrations of HAL and BHAL were adequate for the treatment of uncomplicated falciparum malaria in the 6 patients.

📜 SIMILAR VOLUMES

Pharmacokinetics of an extended-dose hal

Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers*

✍ Ohrt, Colin; Watt, George; Teja-Isavadharm, Paktiya; Keeratithakul, Duangsuda; L 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 811 KB

The pharmacokinetics and tolerance of a 4.5 gm 7&y halofantrine loading dose regimen were evaluated in 10 Thai patients with malaria and in 10 noninfected volunteers. Halofantrine peak plasma concentrations and bioavailability on the first day of treatment were significantly lower in patients with m

Comparative cardiac effects of halofantr

Comparative cardiac effects of halofantrine and chloroquine plus chlorpheniramine in children with acute uncomplicated falciparum malaria

✍ A. Sowunmi; F.A. Fehintola; O.A.T. Ogundahunsi; A.B. Ofi; T.C. Happi; A.M.J. Odu 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 791 KB

The cardiac effects ofhalofantrine (HF) and chloroquine plus chlorpheniramine (CQ-CP), a histamine Hi antagonist which reverses chloroquine insensitivity in Plasmodium falciparum in vitro and in vivo, were assessed in 41 children with acute svmntomatic uncomnlicated P fa&arum malaria bv electrocardi

Problems in the therapy of mixed malaria

Problems in the therapy of mixed malarial infections: a case of infection with Plasmodium falciparum and P. malariae treated with mefloquine and halofantrine

✍ F.J. Hess; H.D.A. Kilian; H.D. Nothdurft; T. Löscher 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 157 KB

The pharmacokinetics of melphalan in pat

The pharmacokinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen

✍ K. W. Woodhouse; P. Hamilton; A. Lennard; M. D. Rawlins 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 210 KB

Pharmacokinetics of IV and oral acetyl-L

Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type

✍ L. Parnetti; A. Gaiti; P. Mecocci; D. Cadini; U. Senin 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 419 KB

A comparison of the pharmacokinetics of

A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria

✍ J. Karbwang; D. J. Back; D. Bunnag; A. M. Breckenridge 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 390 KB